Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ipilimumab and Neoadjuvant Chemotherapy in NSCLC
NCT01820754Phase 2Completed
- Sponsor
- Duke University
- Start
- Mar 2013
- Primary completion
- Apr 2018
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of ipilimumab in non-small cell lung cancer (NSCLC), sponsored by Duke University. Started Mar 2013; status: completed.
02
Drugs
ipilimumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT01820754.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01820754.